JNK Suppresses Tumor Formation via a Gene-Expression Program Mediated by ATF2

Cell Reports

Volumn 9, Issue 4, 2014, Pages 1361-1374

  Gozdecka, Malgorzata ^a,b   Lyons, Stephen ^a   Kondo, Saki ^a,c   Taylor, Janet ^a,d   Li, Yaoyong ^a   Walczynski, Jacek ^a   Thiel, Gerald ^e   Breitwieser, Wolfgang ^a   Jones, Nic ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UNIVERSITY OF TOKYO   (Japan)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; MESSENGER RNA; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CANCER; MOUSE; NONHUMAN; ONCOGENE RAS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ANIMAL; APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ACTIVATING TRANSCRIPTION FACTOR 2; ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER NEOPLASMS; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RAS PROTEINS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84912141151     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.10.043     Document Type: Article

References (51)

1. Arnold H.K., Sears R.C. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev. 2008, 27:147-158.
2. Baek K.H., Zaslavsky A., Lynch R.C., Britt C., Okada Y., Siarey R.J., Lensch M.W., Park I.H., Yoon S.S., Minami T., et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009, 459:1126-1130.
3. Berger A.J., Kluger H.M., Li N., Kielhorn E., Halaban R., Ronai Z., Rimm D.L. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res. 2003, 63:8103-8107.
4. Bhoumik A., Fichtman B., Derossi C., Breitwieser W., Kluger H.M., Davis S., Subtil A., Meltzer P., Krajewski S., Jones N., Ronai Z. Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc. Natl. Acad. Sci. USA 2008, 105:1674-1679.
5. Breitwieser W., Lyons S., Flenniken A.M., Ashton G., Bruder G., Willington M., Lacaud G., Kouskoff V., Jones N. Feedback regulation of p38 activity via ATF2 is essential for survival of embryonic liver cells. Genes Dev. 2007, 21:2069-2082.
6. Calvisi D.F., Ladu S., Conner E.A., Seo D., Hsieh J.T., Factor V.M., Thorgeirsson S.S. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J.Hepatol. 2011, 54:311-319.
7. Cellurale C., Weston C.R., Reilly J., Garlick D.S., Jerry D.J., Sluss H.K., Davis R.J. Role of JNK in a Trp53-dependent mouse model of breast cancer. PLoS ONE 2010, 5:e12469.
8. Cellurale C., Sabio G., Kennedy N.J., Das M., Barlow M., Sandy P., Jacks T., Davis R.J. Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol. Cell. Biol. 2011, 31:1565-1576.
9. Cellurale C., Girnius N., Jiang F., Cavanagh-Kyros J., Lu S., Garlick D.S., Mercurio A.M., Davis R.J. Role of JNK in mammary gland development and breast cancer. Cancer Res. 2012, 72:472-481.
10. Chen X., Cheung S.T., So S., Fan S.T., Barry C., Higgins J., Lai K.M., Ji J., Dudoit S., Ng I.O., et al. Gene expression patterns in human liver cancers. Mol. Biol. Cell 2002, 13:1929-1939.
11. Chow C.W., Rincón M., Cavanagh J., Dickens M., Davis R.J. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 1997, 278:1638-1641.
12. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. METABRIC Group.
13. Das M., Garlick D.S., Greiner D.L., Davis R.J. The role of JNK in the development of hepatocellular carcinoma. Genes Dev. 2011, 25:634-645.
14. Dolado I., Swat A., Ajenjo N., De Vita G., Cuadrado A., Nebreda A.R. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007, 11:191-205.
15. Eferl R., Ricci R., Kenner L., Zenz R., David J.P., Rath M., Wagner E.F. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 2003, 112:181-192.
16. Esteva F.J., Sahin A.A., Smith T.L., Yang Y., Pusztai L., Nahta R., Buchholz T.A., Buzdar A.U., Hortobagyi G.N., Bacus S.S. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 2004, 100:499-506.
17. Galmiche A., Chauffert B., Barbare J.C. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett. 2014, 346:159-162.
18. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
19. Gupta S., Campbell D., Dérijard B., Davis R.J. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995, 267:389-393.
20. Hübner A., Mulholland D.J., Standen C.L., Karasarides M., Cavanagh-Kyros J., Barrett T., Chi H., Greiner D.L., Tournier C., Sawyers C.L., et al. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc. Natl. Acad. Sci. USA 2012, 109:12046-12051.
21. Hui L., Bakiri L., Mairhorfer A., Schweifer N., Haslinger C., Kenner L., Komnenovic V., Scheuch H., Beug H., Wagner E.F. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat. Genet. 2007, 39:741-749.
22. Hui L., Zatloukal K., Scheuch H., Stepniak E., Wagner E.F. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J.Clin. Invest. 2008, 118:3943-3953.
23. Jaworski M., Buchmann A., Bauer P., Riess O., Schwarz M. B-raf and Ha-ras mutations in chemically induced mouse liver tumors. Oncogene 2005, 24:1290-1295.
24. Knippen S., Löning T., Müller V., Schröder C., Jänicke F., Milde-Langosch K. Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas. Anticancer Res. 2009, 29:183-189.
25. Labrakakis C., Patt S., Hartmann J., Kettenmann H. Functional GABA(A) receptors on human glioma cells. Eur. J. Neurosci. 1998, 10:231-238.
26. Lee S., Oh T., Chung H., Rha S., Kim C., Moon Y., Hoehn B.D., Jeong D., Lee S., Kim N., et al. Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer. Int. J. Oncol. 2012, 40:889-898.
27. Lei K., Nimnual A., Zong W.X., Kennedy N.J., Flavell R.A., Thompson C.B., Bar-Sagi D., Davis R.J. The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol. Cell. Biol. 2002, 22:4929-4942.
28. Ma J., Arnold H.K., Lilly M.B., Sears R.C., Kraft A.S. Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A. Oncogene 2007, 26:5145-5153.
29. Maekawa T., Shinagawa T., Sano Y., Sakuma T., Nomura S., Nagasaki K., Miki Y., Saito-Ohara F., Inazawa J., Kohno T., et al. Reduced levels of ATF-2 predispose mice to mammary tumors. Mol. Cell. Biol. 2007, 27:1730-1744.
30. Maekawa T., Sano Y., Shinagawa T., Rahman Z., Sakuma T., Nomura S., Licht J.D., Ishii S. ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors. Oncogene 2008, 27:1045-1054.
31. Müller M.R., Rao A. NFAT, immunity and cancer: a transcription factor comes of age. Nat. Rev. Immunol. 2010, 10:645-656.
32. Newell P., Toffanin S., Villanueva A., Chiang D.Y., Minguez B., Cabellos L., Savic R., Hoshida Y., Lim K.H., Melgar-Lesmes P., et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin invivo. J.Hepatol. 2009, 51:725-733.
33. Raingeaud J., Whitmarsh A.J., Barrett T., Dérijard B., Davis R.J. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol. 1996, 16:1247-1255.
34. Rodgers J.T., Vogel R.O., Puigserver P. Clk2 and B56β mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt. Mol. Cell 2011, 41:471-479.
35. Roessler S., Jia H.L., Budhu A., Forgues M., Ye Q.H., Lee J.S., Thorgeirsson S.S., Sun Z., Tang Z.Y., Qin L.X., Wang X.W. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010, 70:10202-10212.
36. Sakurai T., Maeda S., Chang L., Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. USA 2006, 103:10544-10551.
37. Salh B., Marotta A., Wagey R., Sayed M., Pelech S. Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. Int. J. Cancer 2002, 98:148-154.
38. Shah M., Bhoumik A., Goel V., Dewing A., Breitwieser W., Kluger H., Krajewski S., Krajewska M., Dehart J., Lau E., et al. A role for ATF2 in regulating MITF and melanoma development. PLoS Genet. 2010, 6:e1001258.
39. Shibata W., Maeda S., Hikiba Y., Yanai A., Sakamoto K., Nakagawa H., Ogura K., Karin M., Omata M. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res. 2008, 68:5031-5039.
40. Stark M.S., Woods S.L., Gartside M.G., Bonazzi V.F., Dutton-Regester K., Aoude L.G., Chow D., Sereduk C., Niemi N.M., Tang N., et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 2012, 44:165-169.
41. Steinmüller L., Thiel G. Regulation of gene transcription by a constitutively active mutant of activating transcription factor 2 (ATF2). Biol. Chem. 2003, 384:667-672.
42. Stephens P.J., Tarpey P.S., Davies H., Van Loo P., Greenman C., Wedge D.C., Nik-Zainal S., Martin S., Varela I., Bignell G.R., et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486:400-404. Oslo Breast Cancer Consortium (OSBREAC).
43. Su L., Sampaio A.V., Jones K.B., Pacheco M., Goytain A., Lin S., Poulin N., Yi L., Rossi F.M., Kast J., et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012, 21:333-347.
44. Thomas D.J., Rosenbloom K.R., Clawson H., Hinrichs A.S., Trumbower H., Raney B.J., Karolchik D., Barber G.P., Harte R.A., Hillman-Jackson J., et al. The ENCODE Project at UC Santa Cruz. Nucleic Acids Res. 2007, 35:D663-D667. ENCODE Project Consortium.
45. Ventura J.J., Tenbaum S., Perdiguero E., Huth M., Guerra C., Barbacid M., Pasparakis M., Nebreda A.R. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat. Genet. 2007, 39:750-758.
46. Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 2009, 9:537-549.
47. Walczynski J., Lyons S., Jones N., Breitwieser W. Sensitisation of c-MYC-induced B-lymphoma cells to apoptosis by ATF2. Oncogene 2014, 33:1027-1036.
48. Wang S., Kang X., Cao S., Cheng H., Wang D., Geng J. Calcineurin/NFATc1 pathway contributes to cell proliferation in hepatocellular carcinoma. Dig. Dis. Sci. 2012, 57:3184-3188.
49. Wurmbach E., Chen Y.B., Khitrov G., Zhang W., Roayaie S., Schwartz M., Fiel I., Thung S., Mazzaferro V., Bruix J., et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007, 45:938-947.
50. Yang Y.M., Bost F., Charbono W., Dean N., McKay R., Rhim J.S., Depatie C., Mercola D. C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin. Cancer Res. 2003, 9:391-401.
51. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., Fan S.T., Luk J.M., Wigler M., Hannon G.J., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125:1253-1267.